What Droia Ventures does

Droia Ventures is a specialist biotech venture capital firm founded in 2015 (per company history), headquartered in Zaventem, Belgium with its primary legal entity Droia SA registered in Luxembourg. The firm invests exclusively in therapeutics for oncology and genetic disease, deploying capital globally into young drug development companies that use novel science and innovative approaches to address previously unsolvable clinical problems. Droia manages over EUR 450 million (USD 550 million) across parallel fund vehicles, including the EUR 220 million Droia Genetic Disease Fund closed in May 2021, and reports 25+ portfolio companies with operations spanning the US, Europe, and Asia.

Droia's core offering combines equity investment with active operational involvement. The firm creates new companies, invests in existing companies, and takes interim roles within portfolio companies to accelerate development from company creation through clinical proof of concept. Droia Labs, a wholly-owned R&D subsidiary operating from Leuven, Belgium, functions as the firm's scientific arm, providing state-of-the-art facilities and in-house scientists to validate novel therapeutic ideas and support portfolio company research. The firm's scientific and operational bench includes Managing Partners Janwillem Naesens (Oncology) and Luc Dochez (Genetic Disease), Partner George Golumbeski (former Celgene EVP of Business Development), and venture partners drawn from Moderna, CRISPR Therapeutics, and Sana Biotechnology.

Revenue is generated through traditional venture capital mechanics: management fees on committed/invested AUM and carried interest on realized exits from successful portfolio companies. The firm has produced multiple liquidity events, including the acquisition of Tusk Therapeutics by Roche and IPOs of Arcus Biosciences (NYSE:RCUS), Aura Biosciences (NASDAQ:AURA), and Cyteir Therapeutics (Nasdaq:CYT). Customer segments comprise early-stage biotech companies seeking specialist investor support beyond capital, and institutional limited partners providing fund commitments. The firm co-invests with tier-one partners including Novartis Venture Fund, Forbion, Polaris Partners, and ARCH Venture Partners.

Name

Droia Ventures

Legal name

Droia SA

Website

https://droiaventures.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biotechnology Venture Capital

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Fintech / Insurtech CVC (Financial-services-led CVC) (FSANAHAK)

akta.pro secondary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Venture capital investing
• Biotech seed funding
• Oncology therapeutics investment
• Genetic disease funding
• Drug development financing

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Fund Management: Droia generates revenue through management fees and carried interest from fund returns on successful portfolio company exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Droia Ventures is a specialist early-stage venture capital firm that invests globally in young drug development companies developing therapeutics for oncology and genetic diseases. The firm provides equity capital alongside hands-on operational support from company creation through clinical proof of concept, including taking interim management roles within portfolio companies. Droia Labs, its in-house scientific arm, validates novel therapeutic ideas through state-of-the-art research facilities, while the firm manages over EUR 450 million (USD 550 million) across multiple funds including the EUR 220 million Droia Genetic Disease Fund.

Product overview

Droia Ventures is a specialist biotech venture capital firm offering investment services exclusively focused on therapeutics for oncology and genetic diseases. The core offering consists of investment capital and hands-on operational support through company creation, development acceleration, and clinical proof of concept. Droia Labs serves as the scientific arm providing state-of-the-art research facilities and expert scientific personnel to validate novel ideas for portfolio companies. The firm manages over EUR 450 million (USD 550 million) across multiple funds, with the recently launched Droia Genetic Disease Fund (EUR 220 million) expanding their genetic disease investment activities alongside their established oncology funds.

Differentiator

Problem solved

Functional benefit

Brands

• Droia Labs: Scientific arm of Droia Ventures that validates novel ideas for young drug development companies

Products and services

• Droia Ventures Investment Services Specialist biotech venture capital investment services focused exclusively on therapeutics for oncology and genetic diseases. The firm invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients, providing hands-on support from company creation through clinical proof of concept.
• Droia Labs The scientific arm of Droia Ventures that validates novel ideas for young drug development companies. Provides state-of-the-art facilities to deliver cutting-edge science on groundbreaking ideas, with a team of seasoned scientists and entrepreneurs contributing to delivering life-changing medicines to patients.
• Droia Genetic Disease Fund A specialized investment fund of EUR 220 million (USD 265 million) targeting genetic diseases, applying the same specialist investment strategy as Droia's oncology-focused funds. Creates new startups and supports young existing companies financially and scientifically in developing platforms and bringing drug candidates to patients.
• Droia Oncology Ventures Oncology-focused fund vehicle of Droia Ventures that invests in young drug development companies developing novel cancer therapeutics.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Versant Ventures: Versant Ventures is a healthcare-focused venture firm with operations across the US, Canada, and Europe. It invests across biotech stages and therapeutic areas with a model that combines company creation with traditional venture investing, comparable to Droia's specialist approach.
• Atlas Venture: Atlas Venture is a Boston-based early-stage biotech VC that builds companies from inception and supports them through clinical proof of concept. Its model of company creation and hands-on operational support closely mirrors Droia's investment approach, making it a directly comparable peer.
• RA Capital Management: RA Capital is a Boston-based healthcare-focused investment firm with both public and private strategies, including company creation. Dr. Rez Halse (now at Droia) previously led RA Ventures and the company creation incubator, making RA Capital a directly comparable specialist biotech investor.
• Polaris Partners: Polaris Partners is a US-based venture firm with a dedicated healthcare/biotech practice. It co-invests in Droia portfolio companies including Volastra, Muna Therapeutics, and Montis Biosciences, making it a directly comparable specialist investor in early-stage therapeutics.
• ARCH Venture Partners: ARCH Venture Partners is a US-based early-stage biotech VC that co-invests in Droia portfolio companies (e.g., Volastra Therapeutics). With a long track record of founding biotech companies from novel science, it is a directly comparable specialist biotech investor.
• Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds across biotech stages. As a frequent co-investor with Droia (e.g., Protego Biopharma Series B), Forbion is a directly comparable specialist biotech VC with overlapping portfolio companies and a similar European footprint.
• Novo Holdings (Novo Seeds): Novo Holdings manages the Novo Seeds and Novo Ventures funds, investing in early-stage biotech with a focus on therapeutics and platform technologies. It co-led Muna Therapeutics' Series A with Droia, placing it in the same European biotech specialist peer set.
• Novartis Venture Fund: Novartis Venture Fund is a corporate venture capital arm of Novartis focused on early-stage biotech therapeutics. It co-led Protego Biopharma's $130M Series B with Droia's participation, making it a directly comparable investor in the same oncology and rare disease therapeutic categories.
• EQT Life Sciences (formerly LSP): EQT Life Sciences is a European healthcare and life sciences specialist investor managing growth and venture funds across biotech and medtech. As a similarly-positioned European biotech VC with comparable AUM scale and therapeutic breadth, it is a directly comparable peer.

Emerging players

• 5AM Ventures: 5AM Ventures is an early-stage venture firm focused on creating and investing in life sciences companies. While smaller in AUM than the larger specialist VCs, it shares Droia's focus on building biotech companies from novel science with hands-on operational support.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/droia

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments39 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Droia Ventures